An email has been sent to your address with instructions for changing your password.
There is no user registered with this email.
Sign Up
To create a free account, please fill out the form below.
Thank you for signing up!
A confirmation email has been sent to your email address. Please check your email and follow the instructions in the message to complete the registration process. If you do not receive the email, please check your spam folder or contact us for assistance.
Welcome to our platform!
Oops!
Something went wrong while trying to create your new account. Please try again and if the problem persist, Email Us to receive support.
Mirum Pharmaceuticals, Inc. (NASDAQ: MIRM) will announce its first quarter 2024 financial results on May 8, 2024, followed by a conference call to discuss recent corporate progress. The call will be accessible via phone or webcast.
Mirum Pharmaceuticals, Inc. (NASDAQ: MIRM) annuncerà i risultati finanziari del primo trimestre del 2024 l'8 maggio 2024, seguiti da una conferenza telefonica per discutere dei recenti progressi aziendali. La chiamata sarà accessibile sia telefonicamente che tramite webcast.
Mirum Pharmaceuticals, Inc. (NASDAQ: MIRM) anunciará sus resultados financieros del primer trimestre de 2024 el 8 de mayo de 2024, seguido por una llamada de conferencia para discutir el progreso corporativo reciente. La llamada se podrá acceder por teléfono o webcast.
미럼 파마슈티컬스(Mirum Pharmaceuticals, Inc., 나스닥: MIRM)는 2024년 5월 8일에 2024년도 1분기 재무 결과를 발표할 예정이며, 최근 회사의 진전에 대해 논의하기 위한 전화 회의를 개최할 예정입니다. 전화 회의는 전화 또는 웹캐스트를 통해 접속할 수 있습니다.
Mirum Pharmaceuticals, Inc. (NASDAQ: MIRM) annoncera ses résultats financiers pour le premier trimestre 2024 le 8 mai 2024, suivis d'une conférence téléphonique pour discuter des progrès récents de l'entreprise. L'appel sera accessible par téléphone ou par webdiffusion.
Mirum Pharmaceuticals, Inc. (NASDAQ: MIRM) wird am 8. Mai 2024 die Finanzergebnisse des ersten Quartals 2024 bekannt geben, gefolgt von einer Telefonkonferenz zur Erörterung des jüngsten Unternehmensfortschritts. Die Konferenz kann über Telefon oder Webcast verfolgt werden.
Positive
None.
Negative
None.
FOSTER CITY, Calif.--(BUSINESS WIRE)--
Mirum Pharmaceuticals, Inc. (NASDAQ: MIRM) today announced that it will report first quarter 2024 financial results on May 8, 2024. Mirum will also host a conference call to discuss the first quarter 2024 financial results and recent corporate progress.
Conference call details:
Wednesday, May 8, 2024
4:30 p.m. ET / 1:30 p.m. PT
You may also access the call via webcast by visiting the Events & Presentations section on Mirum’s website. A replay of this webcast will be available for 30 days.
LIVMARLI, an IBAT inhibitor, is approved for the treatment of two rare liver diseases affecting children and adults. It is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome in the U.S. (three months and older), in Europe (two months and older), and in other regions globally. It is also approved in the U.S. in cholestatic pruritus in PFIC patients five years of age and older. Mirum has submitted for approval in Europe for the treatment of PFIC in patients two months of age and older. CHOLBAM is FDA-approved for the treatment of bile acid synthesis disorders due to single enzyme deficiencies and adjunctive treatment of peroxisomal disorders in patients who show signs or symptoms or liver disease. CHENODAL has received medical necessity recognition by the FDA to treat patients with cerebrotendinous xanthomatosis (CTX).
Mirum’s late-stage pipeline includes two investigational treatments for debilitating liver diseases. Volixibat, an IBAT inhibitor, is being evaluated in two potentially registrational studies including the Phase 2b VISTAS study for primary sclerosing cholangitis and Phase 2b VANTAGE study for primary biliary cholangitis. Lastly, CHENODAL, has been evaluated in a Phase 3 clinical study, RESTORE, to treat patients with CTX, with positive topline results reported in 2023.
When will Mirum Pharmaceuticals announce its first quarter 2024 financial results?
Mirum Pharmaceuticals will announce its first quarter 2024 financial results on May 8, 2024.
How can I access the conference call to discuss the financial results?
You can access the conference call by dialing the provided phone numbers or by visiting the Events & Presentations section on Mirum's website for the webcast.
What is the passcode for the conference call?
The passcode for the conference call is 479107.
How long will the webcast replay be available?
The webcast replay will be available for 30 days after the call.
